Diels–Alder Reaction for Tumor Pretargeting: In Vivo Chemistry Can Boost Tumor Radiation Dose Compared with Directly Labeled Antibody
Journal of Nuclear Medicine2013Vol. 54(11), pp. 1989–1995
Citations Over TimeTop 10% of 2013 papers
Abstract
The in vivo performance of chemical pretargeting falls within the range of results obtained for the clinically validated pretargeting approaches in mice, with the advantage of potentially allowing for fractionated radiotherapy as a result of a lower likelihood of immunogenicity. These findings demonstrate that biologic pretargeting concepts can be translated to rapid bioorthogonal chemical approaches with retained potential.
Related Papers
- → IEDDA: An Attractive Bioorthogonal Reaction for Biomedical Applications(2021)68 cited
- → A Bone-Seeking trans-Cyclooctene for Pretargeting and Bioorthogonal Chemistry: A Proof of Concept Study Using 99mTc- and 177Lu-Labeled Tetrazines(2016)47 cited
- → Development of a novel antibody–tetrazine conjugate for bioorthogonal pretargeting(2016)44 cited
- → Recent Advances in Targeting Nuclear Molecular Imaging Driven by Tetrazine Bioorthogonal Chemistry(2019)9 cited
- → Development of the First Aliphatic 18F-Labeled Tetrazine Suitable for Pretargeted PET Imaging – Expanding the Bioorthogonal Tool Box(2021)3 cited